RxDoctor Payments Data

Gary Oppenheim, MD

Cardiovascular Disease · Seattle, WANPI 1083639249

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $126,277 of the $152,860 with a category attached, or 82.6%. 12 manufacturers reported payments, led by Boehringer Ingelheim at 37.7% of the total. Reporting peaked in 2019 at $78,803 and has fallen 95.4% since, to $3,632 in 2023. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$152,860in general payments, 2019–2025

Across 177 payments — averaging $863.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$58K
  • Amgen$31K
  • Novo Nordisk$19K
  • Lilly USA, LLC$17K
  • Regeneron Healthcare Solutions, Inc.$8K
  • Amarin Pharma, Inc.$8K
  • plus $13K from 6 others

What the payments were for

  • Consulting fees$3,3752%
  • Speaking & faculty fees$126,27783%
  • Travel & lodging$18,50212%
  • Food & beverage$4,5773%
  • Education$1290%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,860 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$67,131
Medicare patients
858
Services billed
1,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$101,004
Repatha SureclickEvolocumab104$94,859
Praluent PenAlirocumab28$36,312
JardianceEmpagliflozin30$34,151
VascepaIcosapent Ethyl37$24,405
OzempicSemaglutide18$20,109
WegovySemaglutide12$15,929
Telmisartan136$4,314
Ezetimibe166$3,869
Rosuvastatin Calcium151$1,793
Metoprolol Succinate130$1,686
Ramipril63$1,126
Atorvastatin Calcium104$1,027
Amlodipine Besylate128$944
SotalolSotalol Hcl20$476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$18,554$36,03830 claims
Boehringer IngelheimJardiance$57,553$34,15130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →